drugset
drugset / Trial / NCT01766518

The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)

NCT01766518 ↗

Phase 4 Unknown 120 enrolled Chong Kun Dang Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

Efficacy and safety of MY-REPT capsule in primary, liver transplantation recipients

Timeline

Start
2009-11
Primary completion
2014-04
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule 500 mg Oral
Subject Mycophenolate Mofetil Small molecule 1500 mg Oral

Indications

No indication recorded.